Active, Not Recruiting
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- Research Site Los Angeles, California, United States
- Research Site Orange, California, United States
- Research Site San Francisco, California, United States
- Research Site Washington D.C., District of Columbia, United States